We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




The tRNA Splicing Endonuclease Modulates Cell Division

By Biotechdaily staff writers
Posted on 12 May 2004
Researchers studying cell replication at the molecular level have learned that the human tRNA splicing endonuclease enzyme complex has functions related to both pre-tRNA splicing and to pre-mRNA 3' (3-prime) end formation, indicating a central role in controlling the process of cell division.

tRNA splicing removes introns, the nucleotide sequences in eukaryotes that must be excised from a structural gene transcript in order to convert the transcript into a mature messenger RNA molecule containing only coding sequences that can be translated into the amino acid sequence of a polypeptide. More...
The splicing is catalyzed by tRNA splicing endonuclease. Failure of this enzyme to function results in rapid and uncontrolled cell division leading to diseases such as leukemia, lymphoma, multiple myeloma, solid tumors, and inflammatory diseases such as psoriasis.

Investigators at the drug discovery company PTC Therapeutics, Inc. (South Plainfield, NJ, USA) have identified and characterized the human tRNA splicing endonuclease enzyme complex. They reported in the April 30, 2004, issue of Cell that the enzyme consists of HsSen2, HsSen34, HsSen15, and HsSen54, which are homologues of tRNA endonuclease subunits previously found in yeast. When siRNA was used to deplete SEN2, defects were found in maturation of both pre-tRNA and pre-mRNA.

Senior author Dr. Christopher R. Trotta, a senior scientist at PTC Therapeutics, said, "Overexpression of tRNA and mRNA is a key factor in the deregulation of translation that allows cancer cells to grow uncontrollably. This newly discovered biochemical pathway represents an Achilles' heel of tumor cell growth and opens a new door in the development of therapeutics.”




Related Links:
PTC Therapeutics

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Urine Analyzer
respons® UDS100
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.